Key Takeaways
- • Baltimore raised $62.1 million across 24 deals in Q3 2026, a roughly 9% quarter-over-quarter decrease in capital, though deal count rose from the prior quarter, according to the PitchBook-NVCA Venture Monitor as reported by Technical.ly.
- • Two mega-deals accounted for roughly half of Baltimore's Q3 capital, and the largest Baltimore-area deal was Balance Theory's $19 million Series A.
- • Maryland Momentum Fund managing director Mike Ravenscroft says early-stage life sciences funding remains the region's main concern, with startups delaying raises to gather preclinical data.
- • Maryland raised $247 million across 56 deals in Q3 excluding the $380 million Blue Energy deal, which PitchBook reassigned to Q3 from Q2; Georgiamune ($92.7 million) and Theradaptive ($36.2 million) took most of that capital.
- • Nationally, 82% of VC funding in 2026 has gone to AI startups, and capital is concentrated within fewer deals than at any point this decade.
Summary
Baltimore's venture capital activity dipped slightly in the third quarter of 2026. According to the latest PitchBook and National Venture Capital Association Venture Monitor report, the region raised $62.1 million across 24 deals, a roughly 9% decrease from the prior quarter. Deal count nonetheless increased from the previous quarter. Two mega-deals accounted for half of the total capital. The largest Baltimore-area transaction was a $19 million Series A for Balance Theory, a Columbia-based cybersecurity firm.
The concentration of capital mirrors a national pattern. According to the report, 82% of all venture capital in 2026 has gone to AI startups, and total funding has already surpassed the record set in 2021. The report states that capital is "concentrated within fewer deals than at any point this decade." AI and software companies that can scale with fewer resources are attracting investors, while life sciences companies, which require substantial funding for clinical trials, face a more difficult climate.
Mike Ravenscroft, managing director of the Maryland Momentum Fund, welcomed the activity in cybersecurity but said the stalled pipeline for early-stage life sciences companies concerns him. At his University System of Maryland-sponsored fund, several startups have delayed raises to collect additional preclinical data for wary investors. Massachusetts, also a biotech hub, has seen a sharp decline in seed funding relative to Series A, according to a state industry trade group. Federal programs offer some relief: the Small Business Innovation Research program was reauthorized last April after a six-month pause, and the Advanced Research Projects Agency for Health, established in 2022, received a slight budget increase from the prior fiscal year, according to Washington Post reporting.
At the state level, PitchBook reassigned the $380 million Blue Energy mega-deal to Q3 because of its final closing date, which had lifted Maryland's Q2 totals. Excluding that deal, Maryland raised $247 million across 56 deals in Q3, up from $83 million across 45 deals in Q2. Georgiamune raised $92.7 million and Theradaptive raised $36.2 million, both clinical-stage life sciences companies. Rimjhim Khandelwal, director of venture advancement at the Greater Baltimore Committee, noted that life sciences companies take considerably longer to commercialize because of regulatory pathways, and called for capitalizing on the current federal and local opportunities.
The concentration of capital mirrors a national pattern. According to the report, 82% of all venture capital in 2026 has gone to AI startups, and total funding has already surpassed the record set in 2021. The report states that capital is "concentrated within fewer deals than at any point this decade." AI and software companies that can scale with fewer resources are attracting investors, while life sciences companies, which require substantial funding for clinical trials, face a more difficult climate.
Mike Ravenscroft, managing director of the Maryland Momentum Fund, welcomed the activity in cybersecurity but said the stalled pipeline for early-stage life sciences companies concerns him. At his University System of Maryland-sponsored fund, several startups have delayed raises to collect additional preclinical data for wary investors. Massachusetts, also a biotech hub, has seen a sharp decline in seed funding relative to Series A, according to a state industry trade group. Federal programs offer some relief: the Small Business Innovation Research program was reauthorized last April after a six-month pause, and the Advanced Research Projects Agency for Health, established in 2022, received a slight budget increase from the prior fiscal year, according to Washington Post reporting.
At the state level, PitchBook reassigned the $380 million Blue Energy mega-deal to Q3 because of its final closing date, which had lifted Maryland's Q2 totals. Excluding that deal, Maryland raised $247 million across 56 deals in Q3, up from $83 million across 45 deals in Q2. Georgiamune raised $92.7 million and Theradaptive raised $36.2 million, both clinical-stage life sciences companies. Rimjhim Khandelwal, director of venture advancement at the Greater Baltimore Committee, noted that life sciences companies take considerably longer to commercialize because of regulatory pathways, and called for capitalizing on the current federal and local opportunities.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.